I-MAB
(NASDAQ: IMAB)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $1.50 | Change: -0.08 | %Change: -5.06% | Volume: 148,522 |
Open: | $ 1.56 | Volume: | 148,522 | |
---|---|---|---|---|
High: | $ 1.61 | Yield(%) | 0.00 | |
Low: | $ 1.50 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 121.70M | |
EPS ($) | 0.68 | Shares Out: | 77.02M |
% Price Change (last 4 weeks): | -15.96 |
---|---|
% Price Change (last 13 weeks): | -13.19 |
% Price Change (last 26 weeks): | -29.78 |
% Price Change (last 52 weeks): | -46.26 |
% Price Change (year to date): | -16.84 |
Return on Equity (%): | -62.61 |
---|---|
Return on Assets (%): | -43.35 |
Return on Invested Capital (%): | -50.03 |
Gross Profit Margin (%): | -82.82 |
---|---|
Net Profit Margin (%): | -5302.03 |
Operating Profit Margin (%): | -4471.20 |
|
|
50-day Moving Average: | $1.77 |
---|---|
200-day Moving Average: | $1.68 |
Avg. Daily Vol. (last 50 days): | 207,264 |
Avg. Daily Vol. (last 200 days): | 472,452 |
52-wk high: | $3.17 |
52-wk low: | $1.16 |
Bid: | $1.52 |
Ask: | $1.60 |
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.
|
I-MAB
2440 Research Boulevard Suite 400 Rockville MD 20850 Phone: 1.240.745.6330 Fax: n/a http://www.i-mabbiopharma.com |
Earnings (1year) ($): | -2.58 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 2.92 |
Cash Flow ($): | -2.59 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 40.53 |
Price/Book (x): | 0.65 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 5.67 |
---|---|
Current Ratio (x): | 5.67 |
LT Debt/Equity (x): | 1.34 |
Total Debt/Equity (x): | 4.36 |